Find a specific notice:

A revocation to this notice was published on 23 November 2022, Notice No. 2022-go4989.

Notice Type
Departmental
Notice Title

Specification of COVID-19 Vaccines Under Section 5(3) of the COVID-19 Public Health Response Act 2020

Publication Date
25 Feb 2022

Tags

Statutory specification Health COVID-19 COVID-19 Public Health Response Act

Notice Number

2022-go684
Title
View PDF
File Type and Size
PDF (37 KB)

Pursuant to section 5(3)(b) of the COVID-19 Public Health Response Act 2020 I, Dr Ashley Bloomfield, Director-General of Health, Ministry of Health, hereby declare that the doses of each COVID-19 vaccine or combination of COVID-19 vaccines specified in the schedule to this notice are required for a person to be “vaccinated” for the purposes of all or any legislation in, or made under, the COVID-19 Public Health Response Act 2020 that uses this defined term.

This notice revokes and replaces “Specification of COVID-19 Vaccines under section 5(3) of the COVID-19 Public Health Response Act 2020” published in the New Zealand Gazette, 26 November 2021, Notice No. 2021-go5122.

Schedule – doses and type of vaccine required to be treated as vaccinated within New Zealand borders

2 doses of Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2)

2 doses of Moderna (Spikevax, mRNA-1273)

2 doses of AstraZeneca (Covishield, Serum Institute India formulation)

2 doses of AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19)

2 doses of Sinopharm, Beijing (BBIBP-CorV, BIBP vaccine, Covilo)

2 doses of Sinovac (CoronaVac, PiCoVacc).

2 doses of Bharat Biotech (Covaxin, BBV152)

2 doses of Covovax (Serum Institute India Novavax formulation)

2 doses of Novavax (Nuvaxovid, NVX-CoC2373)

1 dose of Janssen / Johnson & Johnson (Janssen COVID-19 Vaccine, Ad26.COV2.S1, JNJ-78436735), alone or in combination with any other vaccine

2 doses of any combination of the following:

  • Pfizer/BioNTech (Comirnaty, Tozinameran, BNT162b2)
  • Moderna (Spikevax, mRNA-1273)
  • AstraZeneca (Oxford/AstraZeneca, Vaxzevria, AZD1222, ChAdOx1 nCoV-19)
  • AstraZeneca (Covishield, Serum Institute India formulation)
  • Sinopharm, Beijing (BBIBP-CorV, BIBP vaccine, Covilo)
  • Sinovac (CoronaVac, PiCoVacc)
  • Bharat Biotech (Covaxin, BBV152)
  • Novavax (Nuvaxovid, NVX-CoC2373)
  • Covovax (Serum Institute India Novavax formulation)

If a person has received 1 or more doses (or for Zydus Cadila or Rasi Cov Pars 1, 2 or 3 doses) of any of the following, then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield) or Janssen vaccine is required to be treated as vaccinated:

  • Sinopharm, Wuhan (WIBP-CorV. Inactivated Vero Cells)
  • Sputnik V (Gamaleya Research Institute of Epidemiology and Microbiology Gam-COVID-Vac)
  • Gamaleya Research Institute of Epidemiology and Microbiology (Sputnik Light)
  • Takeda (TAK-919). Note: this is a Moderna formulation
  • CanSino (Convidecia, PakVac, Ad5-nCoV)
  • Zydus Cadila (ZyCoV-D)
  • Anhui Zhifei Longcom (Zifivax, ZF2001, ZF-UZ-VAC-2001)
  • Minhai Biotechnology Co (Beijing) (KCONVAC, Minhai COVID-19 vaccine)
  • Shifa Pharmed Industrial Co (COVIran Barekat, BIV1-CoVIran)
  • Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR, FBRI (EpiVacCorona, Aurora-CoV)
  • Chumakov Centre (KoviVac)
  • Khazakstan Research Institute for Biological Safety Problems, RIBSP (QazVac, QazCovid-in)
  • Medigen Vaccine Biologics Corporation, MVC (MVC COVID-19 vaccine, MVC-COV1901)
  • Center for Genetic Engineering and Biotechnology, CIGB (Abdala, CIGB-66)
  • Vaxine/Cinna Gen Co. COVAX-19 (SpikeoGen)
  • Biological E. (BioE) Limited (Corbevax, BECOV2D, BECOV2A, BioE COVID-19)
  • Federal Budgetary Research Institution State Research Center of Virology and Biotechnology VECTOR, FBRI (EpiVacCorona-N, EpiVacCorona)
  • Health Institutes of Turkey (Turkovac, ERUCOV-VAC)
  • Instituto Finlay de Vacunas Cuba (Soberana 02, FINLAY-FR-2, Pasteurcovac)
  • National Vaccine and Serum Institute, China (Recombinant SARS-COV-2 Vaccine (CHO Cell), NVSI-0608, Recombinant COVID-19 Vaccine (CHO cell, NVSI-06-08))
  • Organization of Defensive Innovation and Research, Iran (FAKHRAVAC, MIVAC)
  • Razi Vaccine and Serum Research Institute, Iran (Rasi Cov Pars)

If a person has received 2 doses of Instituto Finlay de Vacunas Cuba (Soberana 02, FINLAY-FR-2, Pasteurcovac) and 1 dose of Instituto Finlay de Vacunas Cuba (Soberana Plus, FINLAY-FR-1A), then 1 additional dose of Pfizer/BioNTech, Moderna, AstraZeneca (Vaxzevria or Covishield) or Janssen vaccine is required to be treated as vaccinated.


For the avoidance of doubt, the dose and COVID-19 vaccines specified in this notice are the vaccination requirements for designated General traveller (A) persons and General traveller (B) persons for the purposes of clause 13 of the COVID-19 Public Health Response (Air Border) Order 2021 (“Order”).

This notice comes into effect at 11.59pm on 27 February 2022

Dated at Wellington this 25th day of February 2022.

Dr ASHLEY BLOOMFIELD, Director-General of Health.